When was Surf Bio founded?

Surf Bio was founded in 2021 and raised its 1st funding round 1 year after it was founded.

Where is Surf Bio located?

Surf Bio is headquartered in Palo Alto, United States.

How many employees does Surf Bio have?

As of Jul 01, 2024, the latest employee count at Surf Bio is 3.

Is Surf Bio a funded company?

Surf Bio is a funded company, having raised a total of $16M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Apr 12, 2022.

How much is Surf Bio worth?

The last known valuation of Surf Bio was $***** as of Jan 29, 2026.

When was the latest funding round of Surf Bio?

Surf Bio's latest funding was a $***** Grant (prize money) round on Apr 30, 2024, with participation from 1 investor.

Where does Surf Bio rank among its competitors?

Surf Bio ranks 333rd amongst 3866 active competitors, of which 1267 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Surf Bio?

Surf Bio's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Surf Bio - 2026 Company Profile, Team, Funding & Competitors

Q: Is Surf Bio an acquired company?

Surf Bio got acquired by Halozyme on Jan 28, 2026.

Surf Bio is an acquired company based in Palo Alto (United States), founded in 2021 by Bryan Mazlish. It operates as a Developer of therapeutics for the treatment of multiple diseases. Surf Bio has raised $16M in funding from Xontogeny and Breakout Ventures, with last known valuation of $*****. The company has 3866 active competitors, including 1267 funded and 870 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Developer of therapeutics for the treatment of multiple diseases. The company leverages a novel biotechnology platform to develop therapeutic solutions for diabetes, oncology, infectious diseases, gene therapy, and other therapeutic areas. The company's flagship program is novel, ultra-rapid insulin for the treatment of diabetes.

Website: www.surf.bio/
Email ID: *****@surf.bio

Key Metrics

Founded Year

2021

Location

Palo Alto, United States

Stage

Acquired

Total Funding

$16M in 2 rounds

Latest Funding Round

Grant (prize money), Apr 30, 2024, $*****

Last Known Valuation

$***** as on Jan 29, 2026

Investors

Xontogeny & 2 more

Ranked

333^rd among 3866 active competitors

Employee Count

3 as on Jul 01, 2024

Similar Companies

Jazz Pharmaceuticals & 3623 more

Exit Details

Acquired by Halozyme (Jan 28, 2026)

View Surf Bio's full profile

Surf Bio got acquired by Halozyme on Jan 28, 2026 at an acquisition amount of $*****.

Click here to take a look at Surf Bio's acquisition in detail

Surf Bio has raised a total funding of $16M over 2 rounds. Its first funding round was on Apr 12, 2022. Its latest funding round was a Grant (prize money) round on Apr 30, 2024 for $*****. 1 investor participated in its latest round. Surf Bio has 3 institutional investors.

Here is the list of recent funding rounds of Surf Bio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 30, 2024	2442743	Grant (prize money)	3374031	4749498	6532325	2225239
Apr 12, 2022	6639080	Seed	2362186	6842270	Breakout Ventures & 1 more	2934221

Access funding benchmarks and valuations. Sign up today!

View details of Surf Bio's funding rounds and investors

The founders of Surf Bio is Bryan Mazlish.

Here are the details of Surf Bio's key team members:

Bryan Mazlish: Founder, President and Board Member of Surf Bio and founder of 1 other company.
Contact Info: 1 email address

View details of Surf Bio's Founder profiles and Board Members

Surf Bio's employee count trend

Surf Bio has 3 employees as of Jul 24. Here is Surf Bio's employee count trend over the years:

Uncover Surf Bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Surf Bio include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Surf Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Leaps by Bayer, New Enterprise Associates ... & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
333rd	Surf Bio 2021, Palo Alto (United States), Acquired	Developer of therapeutics for the treatment of multiple diseases	$16M	Xontogeny, Gates & 1 others	57/100